徐明;王伟;于秀淳;

• 1:济南军区总医院骨病科
• 2:山东省临沂市人民医院骨科

摘要(Abstract)：

[目的]探讨影响骨肉瘤术后生存的预后因素。[方法]对40例骨肉瘤患者平均随访56个月,计算5年总生存率及无瘤生存率,选择临床因素及分子生物学指标,采用比例风险模型进行多因素回归分析。[结果]本组5年总生存率为53.78%、无瘤生存率为45.00%;Cox多因素回归分析显示:肿瘤体积、肿瘤细胞坏死率(TCNR)、P-gp的表达是影响骨肉瘤术后预后的独立因素。[结论]肿瘤体积、P-gp的表达与骨肉瘤的预后呈负相关,TCNR与预后呈正相关。肿瘤体积、TCNR、P-gp的表达可作为判断预后的独立指标。

关键词(KeyWords)： 骨肉瘤;预后;回归分析;P-gp;PCNA;TCNR

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 徐明;王伟;于秀淳;

Email:

DOI:

参考文献(References)：

• [1]Bacci G,Longhi A,Bertoni F,et al.Primary high-grade osteosar-coma:comparison between preadolescent and older patients[J].J Ped-iatr Hematol Oncol,2005,27:129-134.
• [2]于秀淳,徐明,王伟,等.不同新辅助化疗方案治疗骨肉瘤的临床观察[J].中国矫形外科杂志,2008,19:1472-1474.
• [3]Bielack SS,Kempf-Bielack B,Delling G,et al.Prognostic factors inhigh-grade osteosarcoma of the extremities or trunk:an analysis of1,702 patients treated on neoadjuvant cooperative osteosarcoma studygroup protocols[J].J Clin Oncol,2002,20:776-790.
• [4]郭全义,卢世璧,张莉,等.骨肉瘤的治疗及生存率的多因素分析[J].中国矫形外科杂志,2006,7:497-499.
• [5]Bacci G,Ferrari S,Bertoni F,et al.Histologic response of high-gradenonmetastatic osteosarcoma of the extremity to chemotherapy[J].ClinOrthop,2001,386:186-196.
• [6]Bentzen SM,Poulsen HS,Kaae S,et al.Prognostic factors in osteosar-comas[J].Cancer,1988,62:194-202.
• [7]Mankin HJ,Hornicek FJ,Rosenberg AE,et al.Survival data for 648patients with osteosarcoma treated at one institution[J].Clin Orthop,2004,429:286-291.
• [8]Bacci G,Briccoli A,Ferrari S,et al.Neoadjuvant chemotherapy for os-teosarcoma of the extremity:long-term results of the Rizzoli’s 4thprotocol[J].Eur J Cancer,2001,37:2030-2039.
• [9]柳剑,郭卫,杨荣利,等.影像学在评估骨肉瘤新辅助化疗效果中的意义[J].中国矫形外科杂志,2008,17:1329-1331.
• [10]Rosen G,Caparros B,Huvos AG,et al.Preoperative chemotherapy forosteogenic sarcoma:selection of postoperative adjuvant chemotherapybased on the response of the primary tumor to preoperative chemother-apy[J].Cancer,1982,49:1221-1230.
• [11]Pakos EE,Ioannidis JP.The association of P-glycoprotein with re-sponse to chemotherapy and clinical outcome in patients with osteosar-coma.A meta-analysis[J].Cancer,2003,98:581-589.
• [12]Nakashima H,Nishidaa Y,Sugiura H,et al.Telomerase,P53 and PC-NA activity in osteosarcoma[J].Eur J Surg Oncol,2003,29:564-567.